Cycle on Aug 4, 2026

I will start by listing the open threads for this topic to see if there are any specific questions or watches that need attention.

I will perform web searches to check the regulatory status of Replimune's RP1 (vusolimogene oderparepvec) in advanced melanoma, as its PDUFA date was August 2, 2026, as well as Moderna's mFlusiva (mRNA-1010) and Belite Bio's tinlarebant.

The advisory committee met on July 30, 2026 and voted 10 to 3 in favor. The PDUFA date was August 2, 2026. Let's see if the FDA has made a decision on RP1 (vusolimogene oderparepvec, brand name TUDRIQEV?) around or after August 2, 2026. I'll search specifically for "Replimune RP1 FDA approval" or "Tudriqev approval" with freshness "week" or "month" to see if a decision was announced.

Let's do a broader search on "Replimune FDA approval" or "Tudriqev approval" to see if there is any announcement from August 2, 3, or 4 (today is August 4). Let's search with freshness "day" or "week" but with a simpler query. Or maybe we can search on Google/Bing for `site:replimune.com` or `site:fda.gov` or general news. Let's do `Replimune FDA approval` sorted by date.

Okay! The FDA decision is still pending or has not been officially announced yet as of August 4, 2026, though the PDUFA date was August 2, 2026. Wait! Let's search specifically for whether there was an approval or a CRL on August 2, 2026 or later, or if the FDA missed the PDUFA date. Let's do a search on Google/Bing.

So the FDA's decision has not been announced as of today, August 4, 2026, even though the PDUFA target action date was August 2, 2026 (which was a Sunday). It is common for the FDA to take a few extra days or for the announcement to lag if it falls on a weekend, or they may have missed the PDUFA date. Let's register a watch or update the existing watch. Wait, we have an existing watch for RP1, which is `019fb532-0016-7ab5-8085-425a945b5ccc`. Since it is a one-shot watch and hasn't officially resolved yet (no approval or CRL announced yet), let's keep checking or see if we should write a note about the AdComm outcome. Wait, let's look at the other watches. - Capricor's deramiocel BLA: after July 29, 2026 CTGTAC advisory committee meeting. Let's check this! In the search results above, we saw: "STAT Plus: FDA expert panel recommends against approval of Capricor's Duchenne...". Let's search for "Capricor deramiocel FDA advisory committee" or "Capricor Duchenne panel vote" to see what happened.

This is a very significant update! The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9-3 on July 29, 2026 that the available evidence *does not* support the effectiveness of Capricor's deramiocel in DMD-related cardiomyopathy. The regulatory decision date is August 22, 2026. This is a crucial development that directly addresses the watch thread `019faae7-d4d4-7d74-a6b7-85d81f6821f0` ("FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy"). Since the final decision is due on August 22, 2026, the watch itself hasn't fully resolved (it is waiting for the final approval or CRL decision), but we should definitely write a finding note on this AdComm outcome and how it impacts the BLA. Let's do some more search on other watches. - Moderna's mFlusiva (mRNA-1010) FDA decision with PDUFA target action date of August 5, 2026 (tomorrow!). Let's search if there has been any early approval or announcement. - Belite Bio's tinlarebant NDA acceptance (60-day review period, expected around early August 2026). Let's search for "Belite Bio tinlarebant NDA FDA acceptance". - Let's check any other recent news on disease outbreaks or public-health moves, or drug approvals since the last cycle. Let's do a general web search.

The FDA's decision on Moderna's mFlusiva (mRNA-1010) is tomorrow, August 5, 2026. This is a highly anticipated milestone. We can note that it's on the cusp of approval. Let's check Belite Bio's tinlarebant NDA status. The watch `019ec855-8c35-71a4-b33b-90db344bf45d` is "FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant" with target date August 11, 2026. Let's see if there's any update on Belite Bio's tinlarebant NDA acceptance.

Excellent. Belite Bio's tinlarebant FDA filing acceptance/rejection is still pending as they are currently "more than halfway into the ensuing 60-day review period" as of August 3, 2026. This aligns with our watch date of August 11, 2026. Wait, let's look at other science and health news. Is there any major trial readout, disease outbreak, or space/energy breakthrough in the last week? Let's do a search for "clinical trial readout" or "FDA approval" or "outbreak" or "space" or "fusion" or "superconductor" or "disease" with freshness "week" to see if there are other exciting stories to report. Let's do a general web search.

The Otsuka press release is huge news! Let's fetch that page or look at Otsuka's VISIONARY trial data for Voyxact (sibeprenlimab) in IgA Nephropathy (IgAN). The headline is: "Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy". Let's search for this to find the URL and fetch the details. This is an incredible clinical trial readout! IgA nephropathy has been a hot area with several drug candidates (like atrasentan, sparsentan, atacicept). Sibeprenlimab (Voyxact) is an anti-APRIL monoclonal antibody. Let's do a search on this.

This is a major and highly consequential clinical trial readout! Voyxact (sibeprenlimab) is the first selective anti-APRIL monoclonal antibody to demonstrate stabilization of kidney function decline to baseline physiologic rate in adults with primary IgA nephropathy (IgAN) over a two-year Phase 3 trial (VISIONARY). The results are unprecedented. Let's do a quick search on other disease outbreaks or public-health moves, particularly H5N1 bird flu, as there are ongoing watches for bird flu in New Zealand and Australia. Let's see if H5N1 has made any new moves in New Zealand or Australia, or if there is any other significant outbreak. I will search for "H5N1 bird flu Australia" or "H5N1 bird flu New Zealand".

Wow, this is a massive development for the Australia and New Zealand H5N1 watches. Let's review the watches: - `019f2f50-7f4d-7361-8f05-cdf170c2d727` "Australia H5N1 transmission to poultry or local wildlife" (ongoing): "Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies." Wait, the news on August 3, 2026 says: "Agriculture Minister Julie Collins said testing confirmed H5N1 bird flu in a group of 49 dead and 35 sick terns found by helicopter surveillance on rocks off Cape Jaffa... Australia warned on Monday against the risk of a wider spread of H5N1 bird flu after its first mass mortality episode among seabirds killed about 50 greater crested terns...". And on July 29, 2026: "Australia said on July 29 the deadly H5N1 bird flu virus is being transmitted locally in the native bird population... transmission had occurred between greater crested terns in South Australia state." Greater crested terns are wild seabirds, which are wild birds. The watch description says: "Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies." Since greater crested terns are seabirds (shorebirds/seabirds) rather than "native land birds" or "poultry" or "marine mammal colonies", let's check if there has been any other wildlife (like land birds or mammals) affected. But wait! The watch title is "Australia H5N1 transmission to poultry or local wildlife". The description says "commercial poultry flocks, native land birds, or local marine mammal colonies." Wait, local transmission in wild seabirds is happening, and now the first mass mortality event has occurred. This is a massive escalatory catalyst. Let's record an event on this watch thread to capture this first mass mortality event. Since it's an "ongoing" watch, we can record it and set `resolves: false` so it keeps tracking. Let's check New Zealand H5N1 watch: - `019f776d-f69b-75cf-93b1-ae8e6c95e559` "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (ongoing): "Fires when New Zealand confirms H5N1 transmission to commercial poultry operations, wildlife sanctuaries, or local marine mammal colonies." Is there any transmission to poultry or wildlife sanctuaries in New Zealand? The news says New Zealand confirmed its first case last month (July 2026) in a migratory seabird on a Wellington beach, but there are no reports of transmission to poultry or wildlife sanctuaries yet. So we should keep that watch active and untouched, but we can write a finding about the overall H5N1 situation in Oceania (Australia and New Zealand) given the first mass bird deaths in Australia. Let's look at what we should write notes for: 1. **Otsuka's Voyxact (sibeprenlimab) Phase 3 VISIONARY 2-Year eGFR Results**: We don't have a prior finding for Voyxact or sibeprenlimab, except there are related findings for IgAN candidates (like atrasentan and atacicept). Wait! Let's check our prior findings: - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` (score 0.39) - `amgen-tavneos-regulatory-crisis-advocate-retraction` (score 0.38) None of the prior findings are specifically for Otsuka's Voyxact (sibeprenlimab), but we have a watch for "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" and some other IgAN drugs. So we can write a brand new note on Otsuka's Voyxact 2-year Phase 3 VISIONARY data. This is a major clinical trial readout. Let's use the slug `otsuka-voyxact-phase-3-visionary-igan-results`. 2. **Capricor's deramiocel FDA Advisory Committee Vote**: There is an existing watch: `019faae7-d4d4-7d74-a6b7-85d81f6821f0` "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy". Let's check if there's any prior finding. No prior findings are listed for Capricor or deramiocel. Let's write a new finding note for this. Let's use the slug `capricor-deramiocel-dmd-fda-advisory-committee-vote`. 3. **Replimune's RP1 (vusolimogene oderparepvec) FDA Advisory Committee Vote**: An FDA advisory committee voted 10-3 on July 30, 2026 in favor of RP1's efficacy, ahead of its August 2, 2026 PDUFA date. This is a massive turnaround after two previous Complete Response Letters (CRLs). Let's write a new finding note for this. Let's use the slug `replimune-rp1-melanoma-fda-advisory-committee-vote`. 4. **Australia's First H5N1 Mass Wild Bird Mortality Event**: Australia confirmed its first mass mortality event among wild seabirds (greater crested terns) off the South Australian coast, marking a rapid escalation of the H5N1 outbreak in Oceania. Let's write a new finding note for this. Let's use the slug `australia-h5n1-wildlife-mass-mortality-event`. Wait, let's verify if there are any other open threads or watches we can address. - `019fb532-0016-7ab5-8085-425a945b5ccc` "FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma" (one_shot, fire_date Aug 2, 2026). Since the final decision (approval or CRL) has not been announced yet, we cannot resolve this one-shot watch yet. But we can update it or record an event? No, "resolves: true closes a one_shot watch". Since the final decision is still pending, we should keep it open, or maybe we can record a non-resolving event? Wait, `record_event` on a one-shot watch with `resolves: false` keeps it open. But usually, we only call `record_event` when the watch *fires* (which is the final regulatory decision). So let's wait until the final decision is made to resolve/fire it. Wait, let's check if there is any other watch that fired. - `019faae7-d4d4-7d74-a6b7-85d81f6821f0` "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy" (one_shot, fire_date Aug 31, 2026). This is also waiting for the final decision (approval or CRL) on or before August 22, 2026. So we will keep it open. Wait, let's look at the Australia H5N1 watch: - `019f2f50-7f4d-7361-8f05-cdf170c2d727` "Australia H5N1 transmission to poultry or local wildlife" (ongoing). Let's call `record_event` on this watch because the first mass mortality event of wild seabirds (greater crested terns) has been confirmed on August 3, 2026, which represents transmission/spread in local wildlife. Since it is an `ongoing` watch, we set `resolves: false`. Let's do that! Let's write the finding notes first. Let's carefully structure the notes with verbatim quotes, links, and interpretations as required by the instructions. Let's fetch the actual pages or use the detailed search results we got. For Otsuka's Voyxact (sibeprenlimab) Phase 3 VISIONARY trial: - Source: [Otsuka Press Release](https://www.otsuka-us.com/news/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrating-voyxactr) or [Fierce Pharma](https://www.fiercepharma.com/pharma/first-otsuka-voyxact-stabilizes-igan-patients-kidney-function-decline-normal-levels). - Quotes: "Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/year with sibeprenlimab versus -4.2 (95% CI, -4.9 to -3.6) mL/min/1.73 m²/year with placebo" "VOYXACT is the first-and-only U.S. FDA-approved IgAN treatment to show stabilization of kidney function, with evidence of improvement, and a safety profile consistent with placebo over two years" "The VISIONARY two-year eGFR results achieved the KDIGO treatment goal of reducing kidney function decline to near physiological level, fundamentally altering the disease progression." For Capricor's deramiocel FDA Advisory Committee: - Source: [Fierce Biotech](https://www.fiercebiotech.com/biotech/fda-adcomm-shoots-down-capricors-duchenne-cell-therapy-after-meeting-marked-statistical) or [NeurologyLive](https://www.neurologylive.com/view/fda-advisory-committee-votes-against-deramiocel-dmd-cardiomyopathy) or [AJMC](https://www.ajmc.com/view/fda-advisory-panel-votes-against-approval-of-deramiocel-for-dmd). - Quotes: "The Cellular, Tissue, and Gene Therapies Advisory Committee voted to reject the therapy 9 votes to 3. That vote is nonbinding, but it strongly signals a difficult path ahead for the company and deramiocel before the FDA’s August 22 decision date on whether to approve the therapy." (from Inside Precision Medicine) "The committee’s vote was rooted in the fact that the available data did not provide substantial evidence of effectiveness for deramiocel in treating cardiomyopathy in patients with DMD." (from AJMC) For Replimune's RP1: - Source: [CancerNetwork](https://www.cancernetwork.com/view/fda-advisory-committee-backs-rp1-nivolumab-for-advanced-melanoma) or [OncLive](https://www.onclive.com/view/fda-advisory-committee-to-weigh-rp1-plus-nivolumab-in-anti-pd-1-pretreated-advanced-melanoma) or [CureToday](https://www.curetoday.com/view/fda-advisory-committee-backs-rp1-for-advanced-melanoma). - Quotes: "The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 10 to 3 that the benefit-risk profile of vusolimogene oderparepvec (RP1) in combination with nivolumab (Opdivo) is favorable for adult patients with advanced melanoma who have progressed on a prior anti–PD-1–containing regimen." "The vote, came ahead of an August 2, 2026, Prescription Drug User Fee Act (PDUFA) target action date and followed 2 complete response letters (CRLs) across a biologics license application (BLA) process that had stretched through 3 review cycles." For Australia H5N1 Wild Bird Mass Mortality: - Source: [Al Jazeera](https://www.aljazeera.com/news/2026/8/3/australia-warns-h5n1-likely-to-spread-after-first-mass-mortality-episode) or [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/australia-confirms-first-mass-mortality-event-h5-bird-flu-2026-08-03/). - Quotes: "Australia has warned that H5N1 bird flu is likely to spread further, after the country’s first mass mortality episode among seabirds killed about 50 greater crested terns off the coast south of Adelaide." "Once the H5 bird flu is spreading in wildlife and the natural environment, it is not possible to avoid significant losses, which is what we're starting to see now." (Julie Collins, Agriculture Minister) Let's double check if there are other details. I will write these notes now. Wait, let's read the rules on writing notes: - No YAML frontmatter — the title is the first `# ` heading and the slug is the slug parameter you pass. - Name a slug for the DURABLE SUBJECT it tracks. - Every substantive finding MUST cite at least one real source you actually consulted THIS cycle — a web page you fetched, an HN story or comment you read, etc. Do NOT write notes from prior knowledge, training data, or memory. - Carrying 1-2 REPRESENTATIVE VERBATIM QUOTES, copied exactly, each kept with the link it came from. - Wikilink to other findings if applicable. Let's write the first note: `otsuka-voyxact-phase-3-visionary-igan-results` for Otsuka's Voyxact. This is extremely important because it represents a complete paradigm shift in IgAN treatment. Let's formulate the body.

I will write the first research finding on Otsuka's landmark Phase 3 VISIONARY two-year data for Voyxact in IgA nephropathy.

I will write the second finding note on Capricor's deramiocel FDA Advisory Committee vote.